Hutchinson-Gilford progeria syndrome (HGPS) patients do not develop cancer despite a significant accumulation of DNA damage in their cells. We have recently reported that HGPS cells are refractory to experimental oncogenic transformation and we identified the bromodomain-containing 4 protein (BRD4) as a mediator of the transformation resistance. ChIP-sequencing experiments revealed distinct genome-wide binding patterns for BRD4 in HGPS cells when compared to control wild type cells. Here we provide a detailed description of the ChIP-seq dataset (NCBI GEO accession number GSE61325), the specific and common BRD4 binding sites between HGPS and control cells, and the data analysis procedure associated with the publication by Fernandez et al., 2014 in Cell Reports 9, 248-260 [1].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248721 | PMC |
| http://dx.doi.org/10.1016/j.gdata.2014.11.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
DNA-encoded library (DEL) technology has become a powerful tool in modern drug discovery. Fully harnessing its potential requires the use of advanced computational methodologies, which are often available only through proprietary software. This limitation restricts flexibility and accessibility for academic researchers and small biotech companies, hindering the growth of the technology.
View Article and Find Full Text PDFDiscovery of Bi-magnolignan as a novel BRD4 inhibitor inducing apoptosis and DNA damage for cancer therapy.
Biochem Pharmacol
February 2025
State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau 999078, China. Electronic address:
Bi-magnolignan (BM), a novel compound isolated from Magnolia Officinalis leaves, exhibits significant anti-tumor activity in vitro. However, the underlying mechanism remains elusive. This study examines the anti-tumor properties of BM and its mechanism of action, specifically through its interaction with BRD4, a key regulator in oncogene transcription and genome stability.
View Article and Find Full Text PDFPROTAC-induced protein structural dynamics in targeted protein degradation.
Elife
February 2025
Department of Chemistry, University of California, Riverside, Riverside, United States.
PROteolysis TArgeting Chimeras (PROTACs) are small molecules that induce target protein degradation via the ubiquitin-proteasome system. PROTACs recruit the target protein and E3 ligase; a critical first step is forming a ternary complex. However, while the formation of a ternary complex is crucial, it may not always guarantee successful protein degradation.
View Article and Find Full Text PDFThe Bromodomain and Extraterminal Protein Inhibitor Apabetalone Ameliorates Kidney Injury in Diabetes by Regulating Cholesterol Accumulation and Modulating the Gut Microbiota.
Kidney Int Rep
February 2025
Department of Nephrology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Introduction: A US Food and Drug Administration-approved new bromodomain (BRD) and extraterminal (BET) bromine domain antagonist called apabetalone, which targets BRD4, has been shown to increase prebeta-1 high-density lipoprotein (HDL) particles, enhance apolipoprotein A-I in both humans and animals, and restore angiogenesis in experimental diabetes. Its action is not however fully known mechanistically. The objective of our research was to investigate the impact of apabetalone on renal damage linked to diabetic kidney disease (DKD).
View Article and Find Full Text PDFHistone deacetylase inhibitors have been investigated as potential therapeutic agents for cancer and other diseases. HDIs are known to promote histone acetylation, resulting in an open chromatin conformation and generally increased gene expression. In previous work, we reported that a subset of genes, particularly those regulated by superenhancers, can be suppressed by the HDAC inhibitor largazole.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!